1. Minimum Effective Dose of Etodolac for the Treatment of Rheumatoid Arthritis
- Author
-
Jacqueline Kennedy, Marie Sanda, John F. Mullane, Carol Epstein, Marianne Messina, and Ginette Jacob
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Analgesic ,Administration, Oral ,Acetates ,Placebo ,Gastroenterology ,Arthritis, Rheumatoid ,Random Allocation ,Therapeutic index ,Double-Blind Method ,Internal medicine ,Humans ,Medicine ,Pharmacology (medical) ,Antipyretic ,Etodolac ,Aged ,Pharmacology ,Clinical Trials as Topic ,Aspirin ,Dose-Response Relationship, Drug ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Middle Aged ,medicine.disease ,Effective dose (pharmacology) ,Surgery ,Rheumatoid arthritis ,Female ,business ,medicine.drug - Abstract
Etodolac was compared with aspirin and placebo for efficacy and safety, and a minimum effective dose was established in 264 patients with adult-onset, active rheumatoid arthritis. In this six-week, 14-center, double-blind, parallel-group investigation, preceded by a washout period of up to two weeks, patients received daily doses of etodolac at 50, 100, or 200 mg/d; aspirin at 3,900 mg/d; or placebo. Both etodolac at the highest dose and aspirin produced statistically significant improvement from baseline in all disease activity assessments measured at four- and six-week end points and were superior to placebo in the majority of assessments. A greater number of patient complaints occurred with aspirin, especially in regard to gastrointestinal-related and otologic side effects. A significant therapeutic dose response was evident among the etodolac groups without an increase in side effects. Although the 100-mg/d dose was effective in many of the efficacy parameters measured, the 200-mg/d dose, which is comparably efficacious to aspirin 3.9 g/d, was suggested as the minimum effective dose for the relief of the signs and symptoms of active rheumatoid arthritis.
- Published
- 1986